Drug intelligence / Profile preview

VNPP548

Development stage: Preclinical
Lead developer: Isoprene Pharmaceuticals
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

VNPP548 is a preclinical-stage small molecule molecular glue degrader being developed by Isoprene Pharmaceuticals. It serves as a backup compound within the company's pipeline, which focuses on utilizing a non-Cereblon-based platform for targeted protein degradation. Based on its nomenclature (the "VNPP" series), VNPP548 is designed to target the Androgen Receptor (AR), including its splice variants such as AR-V7, and the E3 ubiquitin ligase MDM2. This dual-targeting mechanism is intended to treat castration-resistant prostate cancer (CRPC) by degrading the primary oncogenic driver (AR) while simultaneously stabilizing the p53 tumor suppressor through MDM2 degradation.

Targets

AR (Adrenergic receptors)MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on VNPP548.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNPP548.

Explore the full profile